2013
DOI: 10.1016/j.vaccine.2012.10.101
|View full text |Cite
|
Sign up to set email alerts
|

Hepatitis B vaccination: A completed schedule enough to control HBV lifelong?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
70
2
4

Year Published

2014
2014
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 74 publications
(79 citation statements)
references
References 38 publications
3
70
2
4
Order By: Relevance
“…6,7 Although the role of cellular immunity is not well understood, epidemiological data show that individuals not infected at the time of vaccination almost never develop acute clinical or chronic hepatitis B. 5,8 In conclusion, our results and those from Spradling et al suggest that there is no need for boosters in vaccinated individuals with residual anti-HB antibodies. Financial support for the present analysis: None Potential conflicts of interest: VG, NB, and GDS have received research grants from GlaxoSmithKline and Quebec Ministry of Health and Social Services; GDS has received travel reimbursement from GlaxoSmithKline; DM reports no financial conflicts.…”
Section: Short-and Long-term Effects Of a Challenge Dose Of Hepatitissupporting
confidence: 56%
See 1 more Smart Citation
“…6,7 Although the role of cellular immunity is not well understood, epidemiological data show that individuals not infected at the time of vaccination almost never develop acute clinical or chronic hepatitis B. 5,8 In conclusion, our results and those from Spradling et al suggest that there is no need for boosters in vaccinated individuals with residual anti-HB antibodies. Financial support for the present analysis: None Potential conflicts of interest: VG, NB, and GDS have received research grants from GlaxoSmithKline and Quebec Ministry of Health and Social Services; GDS has received travel reimbursement from GlaxoSmithKline; DM reports no financial conflicts.…”
Section: Short-and Long-term Effects Of a Challenge Dose Of Hepatitissupporting
confidence: 56%
“…Additionally, the loss of antibodies or immune memory (measured as presence of anti-HBs) does not necessarily mean that the individual is not protected against clinical or chronic infection. 5 Recent data suggest the presence of cellular immunity in vaccinated individuals without residual antiHBs. 6,7 Although the role of cellular immunity is not well understood, epidemiological data show that individuals not infected at the time of vaccination almost never develop acute clinical or chronic hepatitis B.…”
Section: Short-and Long-term Effects Of a Challenge Dose Of Hepatitismentioning
confidence: 99%
“…1 To control HBV infection, universal neonatal immunisation with the hepatitis B vaccine was introduced more than 3 decades ago, and its efficacy has been reported in many studies that have shown not only a reduction in the prevalence of childhood HBV infection, but also the presence of an anamnestic response that could maintain immunoprotection for many years. [2][3][4][5][6][7][8][9][10][11][12][13][14] Indeed, in Taiwan, following introduction of the vaccine, the incidence of hepatocellular carcinoma (HCC) in children was reduced from 0.54 to 0.20 per 100,000 children aged 6-14 years in those born before versus after the vaccination program. 15 In Hong Kong, selective active-passive hepatitis B immunization was first administered to neonates born to mothers screened positive for hepatitis B surface antigen (HBsAg) from late 1983 to 1988, 16 followed by universal neonatal HBV vaccination from November 1988, 17 and the vaccine has become widely available since.…”
Section: Introductionmentioning
confidence: 99%
“…É uma das principais doenças hepáticas, apresentando taxas de prevalência variadas, porém altas. A imunização ativa ou passiva contra o HBV é a maneira mais eficaz, acessível e gratuita de prevenção contra esta [3][4] . Tal imunização se dá após a administração de três doses da vacina por via intramuscular.…”
Section: Introductionunclassified
“…Vale salientar que o risco de transmissão de infecção por meio de material pérfuro-cortante é variável entre os principais agente relacionados com acidentes ocupacionais na odontologia, sendo de 1:3 para HBV, 1:30 para hepatite C (HCV) e 1:300 para o vírus da imunodeficiência humana (HIV) 3 . Além disso, sabe-se que a transmissão do HBV também pode ocorrer através de solução de continuidade em pele e mucosas, relações sexuais, transfusão de sangue e hemoderivados, uso de drogas intravenosas, transmissão vertical e contatos domiciliares 6 .…”
Section: Introductionunclassified